MTOR and neoplasm: Combinations of mTOR inhibitors with inhibitors of other pathways, including a trial combining the tyrosine kinase inhibitor sorafenib with mTOR inhibition (Grignani et al., 2015), have also been explored, suggesting that molecular targets based on tumor-specific biomarkers are an active avenue for the development of novel therapies.